Cargando…
Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma
Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-y...
Autores principales: | Lee, Si Won, Lee, Eun Kyung, Yun, Tak, Won, Young-Woong, Ko, Eun Jeong, Choi, Mihong, Choi, Sang Il, Park, Sun Seob, Hong, Eun Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Endocrine Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091496/ https://www.ncbi.nlm.nih.gov/pubmed/25031894 http://dx.doi.org/10.3803/EnM.2014.29.2.202 |
Ejemplares similares
-
Recurrent Meningeal Hemangiopericytoma with Multiple Metastasis and Hypoglycemia: A Case Report
por: Chan, Jammy Kin Iong, et al.
Publicado: (2012) -
Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer()()
por: Choi, Kyung Hwa, et al.
Publicado: (2018) -
Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence
por: Kang, Seong Hee, et al.
Publicado: (2018) -
Nasal Hemangiopericytoma Causing Oncogenic Osteomalacia
por: Cho, Sung Il, et al.
Publicado: (2012) -
Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma
por: Kim, Bo Hyun, et al.
Publicado: (2019)